Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

He's a BODer showing confidence in Spectrum's future.

Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors
Business Wire•November 13, 2018
HENDERSON, Nev.--(BUSINESS WIRE)--

Spectrum Pharmaceuticals Inc., (SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca, MD, FACP to its Board of Directors.
Dr. Vacirca is a practicing oncologist and the current president of the CommunityOncology Alliance, an advocacy group focused on supporting community oncology clinics. Additionally, Dr. Vacirca is the medical director of the nation’s largestcommunity oncology group purchasing organization, International Oncology Network and the CEO and managing partner at North Shore Hematology Oncology Associates. He also serves as the vice chairman at Odonate Therapeutics (ODT), an oncology company focused on treating metastatic breast cancer. Furthermore, he has joined the Board of Directors for One Oncology, an oncologist-led company providing oncologists with innovative tools to help keep cancer care in the hands of the providers.

“As a prominent leader within community oncology, Dr. Vacirca has a reputation and clear understanding of how to successfully develop and commercialize oncology pharmaceuticals,” said Joe Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals. “His expertise working across multiple stakeholders including patient advocacy groups, clinical investigators, group purchasing organizations, and government agencies is invaluable and precisely what is needed as Spectrum advances its two late-stage pipeline products, poziotinib and ROLONTIS.”
“Joining the Spectrum Board provides me the rare opportunity to fulfill a passion for patient care while working with a company developing life changing therapies,” said Dr. Vacirca. “Poziotinib has the potential to change the treatment paradigm for a subset of cancer patients that have had no adequate treatment options. Additionally, Spectrum has developed a novel G-CSF, which is the first new drug in over fifteen years for use in chemotherapy induced neutropenia.”

With Dr. Vacirca’s appointment, the Spectrum Board increases to nine directors, each of whom are nominated annually by the nominating and corporate governance committee.